secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2026-08-24T20:06:13+00:00
Accession:  0001213900-26-093021
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oruka names Todd Edwards Chief Commercial Officer, eff. Aug 24 2026
-------------------------------------------------------------------

- Todd Edwards, ex-CCO of Arcutis Biotech, starts as Oruka's Chief Commercial Officer on Aug 24, 2026, reporting to CEO.
- Annual base salary $525,000; target bonus 40% of base; $200,000 signing bonus repayable prorated if resignation within 1 year.
- Equity grant: 20,000 options + 100,000 RSUs; options vest 25% at 1yr then monthly over 36mo, RSUs quarterly.
- Severance: 12 months base salary outside CIC; within CIC 1.0x (base+target) plus full acceleration of time-based equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000121390026093021/0001213900-26-093021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000121390026093021/ea0302923-8k_oruka.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-093021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer